Weight loss gold rush: Developers vie for next blockbuster treatment

Weight loss treatments are rapidly becoming a focal point for pharma R&D, driven by the commercial success of Eli Lilly and Novo Nordisk’s therapies. With over 100 potential treatments in the pipeline and a surge in innovation, Ben Hargreaves finds the race is on to develop a next-generation solution for obesity.